+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cerebral Adrenoleukodystrophy Market by Type (Diagnosis, Treatment), End-User (Home Care Services, Hospitals & Clinical, Specialty Clinics) - Forecast 2024-2030- Product Image
Global Cerebral Adrenoleukodystrophy Market by Type (Diagnosis, Treatment), End-User (Home Care Services, Hospitals & Clinical, Specialty Clinics) - Forecast 2024-2030- Product Image
Sale

Global Cerebral Adrenoleukodystrophy Market by Type (Diagnosis, Treatment), End-User (Home Care Services, Hospitals & Clinical, Specialty Clinics) - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5968265
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cerebral Adrenoleukodystrophy Market size was estimated at USD 5.36 billion in 2023, USD 5.95 billion in 2024, and is expected to grow at a CAGR of 11.21% to reach USD 11.29 billion by 2030.

Cerebral adrenoleukodystrophy (CALD) is a rare genetic infection that mainly affects the nervous system and adrenal glands, which are small organs on top of each kidney. CALD is a type of leukodystrophy, which refers to a group of disorders characterized by the degeneration of myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. Increased awareness and better screening practices for early diagnosis can lead to improved outcomes, thereby driving the demand for effective treatments.

Government and regulatory support through funding and fast-track approvals for treatments of rare diseases, including CALD, driving the market forward. However, the high cost associated with treatments such as gene therapy and stem cell transplantation limits the market expansion. Furthermore, technological advancements in gene therapy and stem cell research that increase the effectiveness and safety of these treatments pose significant opportunities to the market.

Regional Insights

The American region exhibits a strong infrastructure in healthcare and research, with numerous initiatives aiming at early detection and treatment of CALD. Advances in newborn screening programs across several countries have enhanced early diagnosis, thereby improving the long-term prognosis of affected individuals. Investments in gene therapy and other innovative treatments have shown promising results, with patents reflecting ongoing improvements in targeted therapies. The EU has a strong regulatory framework that supports extensive research and the adoption of new therapies. Countries including Germany, France, and the Netherlands have active newborn screening programs and are leaders in research and clinical trials related to CALD.

The European Medicines Agency (EMA) plays an important role in the rapid approval of innovative treatments. Awareness and resources for CALD are growing in the Middle East, with countries including the UAE and Saudi Arabia investing in healthcare infrastructure and specialist training programs. The APAC region is rapidly advancing in the fields of genomics and biotechnology, with substantial countries' investments & funding directed toward genetic research. The APAC countries with a strong pharmaceutical sector and government-backed healthcare system support advanced research and treatment methodologies.

Market Trends by Segment

  • Type: Ongoing innovations in genetic testing to accelerate the diagnosis of cerebral adrenoleukodystrophy
  • End-User: Specialty clinics play a significant role in ongoing management and specialized treatments

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Breakthrough in Alzheimer’s Disease Diagnosis as Neurocode Launch ALZpath Dx Blood Test

Neurocode announced the clinical release of ALZpath Dx, a cutting-edge blood test designed to detect, diagnose, and monitor Alzheimer's disease (AD). This test measured the circulating levels of phosphorylated tau at position 217 (pTau217), a key biomarker for AD. Utilizing Quanterix Corp's Simoa® technology, ALZpath Dx offered a non-invasive, cost-effective, and highly accurate diagnostic alternative to traditional methods like brain imaging or cerebrospinal fluid tests.

Strategic Collaboration between InSilicoTrials Technologies and Axoltis Pharma to Enhance CNS Drug Development

InSilicoTrials Technologieshas formed a strategic partnership with Axoltis Pharma, which is focused on advancing treatments for neurodegenerative conditions. This collaboration centers around employing InSilicoTrials Technologies's platform, particularly its InSilicoNEURO suite, to explore the effects of Axoltis Pharma's NX210c, a 12-amino acid peptide, on virtual patients with various Central Nervous System (CNS) disorders including Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease, and Multiple Sclerosis.

FDA Approves Phase 3 CALYX Trial for Leriglitazone in Treatment of Cerebral Adrenoleukodystrophy

MINORYX THERAPEUTICS SL has gained approval from the US FDA for its Phase 3 CALYX trial, focusing on leriglitazone as a therapeutic option for adult male patients with cerebral Adrenoleukodystrophy (cALD), a subtype of X-linked Adrenoleukodystrophy (X-ALD). The primary study endpoint included major outcomes such as ‘time to death’ or ‘permanent ventilatory support. Endpoints were built on favorable previous trial outcomes and ongoing compassionate use data. Leriglitazone has shown promise in halting lesion progression, achieving stabilizations paralleled to those seen in hematopoietic stem cell transplant or gene therapy treatments.

Key Company Profiles

The report delves into recent significant developments in the Cerebral Adrenoleukodystrophy Market, highlighting leading vendors and their innovative profiles. These include bluebird bio, Inc., Boston Scientific Corporation, Esaote S.p.A, FUJIFILM Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Medtronic PLC, MINORYX THERAPEUTIS SL, NeuroVia, Inc., Neusoft Corporation, POXEL SA, SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD., Shimadzu Corporation, Siemens AG, Stryker Corporation, and Toshiba Corporation.

This research report offers invaluable insights into various crucial aspects of the Cerebral Adrenoleukodystrophy Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased prevalence and diagnostic rates of CALD
5.1.1.2. Growing healthcare expenditure and insurance coverage
5.1.2. Restraints
5.1.2.1. High cost of treatment and accessibility issues
5.1.3. Opportunities
5.1.3.1. Advancements in therapeutic product development
5.1.3.2. Improvements in gene therapy for precision treatment
5.1.4. Challenges
5.1.4.1. Product development and manufacturing complexities in cerebral adrenoleukodystrophy treatment
5.2. Market Segmentation Analysis
5.2.1. Type: Ongoing innovations in genetic testing to accelerate the diagnosis of cerebral adrenoleukodystrophy
5.2.2. End-User: Specialty clinics play a significant role in ongoing management and specialized treatments.
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Cerebral Adrenoleukodystrophy Market, by Type
6.1. Introduction
6.2. Diagnosis
6.3. Treatment
7. Cerebral Adrenoleukodystrophy Market, by End-User
7.1. Introduction
7.2. Home Care Services
7.3. Hospitals & Clinical
7.4. Specialty Clinics
8. Americas Cerebral Adrenoleukodystrophy Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cerebral Adrenoleukodystrophy Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cerebral Adrenoleukodystrophy Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. Breakthrough in Alzheimer’s Disease Diagnosis as Neurocode Launch ALZpath Dx Blood Test
11.3.2. Strategic Collaboration between InSilicoTrials Technologies and Axoltis Pharma to Enhance CNS Drug Development
11.3.3. FDA Approves Phase 3 CALYX Trial for Leriglitazone in Treatment of Cerebral Adrenoleukodystrophy
11.4. Strategy Analysis & Recommendation
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
List of Figures
FIGURE 1. CEREBRAL ADRENOLEUKODYSTROPHY MARKET RESEARCH PROCESS
FIGURE 2. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CEREBRAL ADRENOLEUKODYSTROPHY MARKET DYNAMICS
FIGURE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. CEREBRAL ADRENOLEUKODYSTROPHY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY MRI, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY MRI, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NEUROLOGICAL TESTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NEUROLOGICAL TESTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADRENAL HORMONE REPLACEMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADRENAL HORMONE REPLACEMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS & CLINICAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS & CLINICAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 47. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 48. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 49. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 50. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 51. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 52. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 53. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 54. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 55. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 56. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 57. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 58. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 59. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 60. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 61. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 62. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 63. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 64. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 65. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 66. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 67. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 68. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 69. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 70. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 71. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 72. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 73. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 74. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 75. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 76. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 77. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 78. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 79. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 80. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 81. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 82. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 83. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 84. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 85. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 86. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 87. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 88. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 89. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 90. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 92. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 94. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 96. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 98. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 100. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 101. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 102. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 103. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 104. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 105. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 106. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 107. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 108. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 109. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 110. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 111. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 112. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 113. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 114. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 115. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 116. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 117. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 118. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 119. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 120. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 121. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 122. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 123. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 124. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 125. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 126. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 127. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 128. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 129. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 130. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 131. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 132. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 133. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 134. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 135. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 136. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 137. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 138. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 139. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 140. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 141. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 142. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 143. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 144. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 145. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 146. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 147. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 148. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 149. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 150. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 151. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 152. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 153. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 154. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 155. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 156. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 157. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 158. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 159. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 160. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 161. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 162. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 163. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 164. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 165. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 166. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 167. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 168. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 169. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 170. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 171. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 172. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 173. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 174. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 175. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 176. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 177. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 178. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 179. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 180. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 181. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 182. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 183. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 184. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 185. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 186. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 187. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 188. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 189. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 190. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 191. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 192. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 193. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 194. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 195. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 196. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 207. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 208. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 209. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 210. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 211. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 212. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 213. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 214. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 215. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 216. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 217. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 218. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 219. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 220. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 221. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 222. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 223. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 224. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 225. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 226. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 227. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 228. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 229. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 230. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 231. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 232. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 233. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 234. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 235. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 236. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 237. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 238. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 239. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 240. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 241. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 242. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 243. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 244. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 245. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 246. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 247. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 248. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 249. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 250. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 251. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 252. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 253. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 254. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 255. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 256. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 257. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 258. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 259. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 260. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 261. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 262. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 263. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 264. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 265. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 266. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 267. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 268. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 269. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 270. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 271. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 272. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 273. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 274. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 275. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 276. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 277. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 278. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 279. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 280. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 281. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 282. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 283. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 284. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 285. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 286. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 287. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 288. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 289. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 290. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 291. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 292. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 293. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 294. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 295. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 296. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 297. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 298. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 299. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 300. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 301. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 302. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 303. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 304. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 305. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 306. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 307. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 308. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 309. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 310. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 312. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 314. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 316. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 318. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 320. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
TABLE 322. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
TABLE 324. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 326. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 327. SPAIN CEREBRAL ADRENO

Companies Mentioned

  • bluebird bio, Inc.
  • Boston Scientific Corporation
  • Esaote S.p.A
  • FUJIFILM Corporation
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips N.V.
  • Medtronic PLC
  • MINORYX THERAPEUTIS SL
  • NeuroVia, Inc.
  • Neusoft Corporation
  • POXEL SA
  • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
  • Shimadzu Corporation
  • Siemens AG
  • Stryker Corporation
  • Toshiba Corporation

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.29 Billion
Compound Annual Growth Rate11.2%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Cerebral Adrenoleukodystrophy - Pipeline Insight, 2024 - Product Image

Cerebral Adrenoleukodystrophy - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Adrenoleukodystrophy - Pipeline Insight, 2024 - Product Image

Adrenoleukodystrophy - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Adrenoleukodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Adrenoleukodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 133 Pages
  • Global
From
Adrenoleukodystrophy Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Adrenoleukodystrophy Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 86 Pages
  • Global
From
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2023 Update - Product Image

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2023 Update

  • Report
  • 85 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.